FDA devotes new resources to upgrading generic drug safety: but in some instances, the industry is pushing back.
نویسنده
چکیده
The Food and Drug Administration, concerned about the quality of the generic drugs that represent 84 percent of U.S. prescriptions, is looking more closely at foreign manufacturing plants and weighing other changes in the generic approval process.
منابع مشابه
Congress is likely to approve generic drug user fees: action should spur faster FDA approvals.
$824 billion in the last decade. The cost savings benefit is obvious, and some even claim that generic products can be safer than their brand-name counterparts. Edith A. Rosato, RPh, Chief Executive Officer at the Academy of Managed Care Pharmacy, explains: “Generic drugs, by definition, are versions of brand-name drugs that have been available in the marketplace for many years. The longer a dr...
متن کاملNew Product Development in the Pharmaceutical Industry: Evidence from Iran
In today’s competitive world, there are several strategies to deal with the fast changing environment, among which New product development (NPD) is a common strategy. However, almost half of the resources that companies devote to NPD are spent on products that may fail. This issue is particularly highlighted in the pharmaceutical industry mainly because of a long development-time, low success r...
متن کاملOverview of the Hatch-Waxman Act and its impact on the drug development process.
There is a paucity of legislative history on the Hatch-Waxman Act. This article will try to provide a general overview of the legislative process and some insight into the Act’s underlying assumptions, with the help of some graphics. With a bill as hardfought as Hatch-Waxman, there was much written about it after the fact, but not a great deal of coherent legislative history. The article also p...
متن کاملIn U.S., biosimilars still await FDA decision.
Offi cials at the U.S. Food and Drug Administration have yet to announce if and when they plan to begin accepting abbreviated applications for follow-on biologics (referred to as " biosimilar " drugs in Europe), but experts said they do not expect anything from the agency soon. Generic biologic agents can still be approved through a new-drug application (NDA), but the burden of proof that comes...
متن کاملNew Product Development in the Pharmaceutical Industry: Evidence from Iran
In today’s competitive world, there are several strategies to deal with the fast changing environment, among which New product development (NPD) is a common strategy. However, almost half of the resources that companies devote to NPD are spent on products that may fail. This issue is particularly highlighted in the pharmaceutical industry mainly because of a long development-time, low success r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 39 5 شماره
صفحات -
تاریخ انتشار 2014